KAIST Identifies 2 Molecular Control Routes to Unlock Irreversible Cancer-like Cell States
Updated
Updated · Aju Press · Aug 21
KAIST Identifies 2 Molecular Control Routes to Unlock Irreversible Cancer-like Cell States
3 articles · Updated · Aju Press · Aug 21
Summary
Published in PNAS on Aug. 18, KAIST’s ROOT method maps the feedback circuits that keep cells stuck in altered states even after the triggering signal disappears.
The computational model simulates a stimulus arriving and then being withdrawn, isolating the small set of loops—an “irreversibility kernel”—from thousands of molecular feedback interactions.
ROOT then points to two intervention strategies: “reset control,” which returns a cell to its earlier state, and “reversing control,” which removes the source of irreversibility.
Tests on B-cell differentiation, lung-cancer epithelial-mesenchymal transition, and enterocyte and beta-cell development matched regulators already identified in prior lab studies.
The work remains entirely computational, with no laboratory reversal of cells yet demonstrated, but KAIST says it clarifies why diseased or aging cells fail to revert on their own.
Could a newly discovered cellular kernel allow us to program cancer cells back to normal instead of destroying them?
What if the secret to reversing human aging is simply debugging a microscopic feedback loop hidden within our cells?
ROOT Technology Unveiled: KAIST’s 2026 Breakthrough Offers Precise Reversal of Cancer and Aging by Unlocking Cellular Feedback Loops
Overview
In August 2026, KAIST scientists introduced ROOT technology, a breakthrough that uses computational models to identify and control the core circuits—called the 'irreversibility kernel'—that lock cells in diseased or aged states. By simulating and targeting these circuits, ROOT offers new resetting and reversing strategies to restore cells to health, avoiding the risks of gene editing and reprogramming. Validated in real biological models, ROOT’s approach is supported by recent regulatory shifts favoring human-relevant, AI-driven drug development. However, its powerful network-level interventions raise safety, ethical, and social justice concerns, making transparent communication and equitable access essential for future acceptance.